Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board

H. Lee Moffitt Cancer Center and Research Institute

Status: Enrolling

Conditions: Incurable Disease

Treatments: Other: Evolutionary Tumor Board (ETB)

Study type: Observational

Funder types: Other

Identifiers

NCT04343365

MCC-20417

Details and patient eligibility

About

This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.

Enrollment: 35 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care.
• Participant must have a life expectancy greater than 3 months
• Participant must have an ECOG performance status 0-2
• Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB
• Willingness to be followed over time and allowing collection of clinical data including scans and serial blood sampling.

Exclusion criteria

• None

Trial design

35 participants in 1 patient group

Participants Reviewed by ETB

Description:

Participants clinical history, available therapeutic options, and outcome expectations will be presented to the Evolutionary Tumor Board (ETB) along with images and pathology. Strategies and models will be presented regarding additional evolutionary ideas that can be applied.

Treatment:

Other: Evolutionary Tumor Board (ETB)